ORIGINAL RESEARCH article
Front. Endocrinol.
Sec. Renal Endocrinology
Volume 16 - 2025 | doi: 10.3389/fendo.2025.1643360
This article is part of the Research TopicInnovative Therapeutic Strategies for Chronic Kidney Disease: From Molecular Mechanisms to Clinical PracticeView all 8 articles
Cholesterol, High-Density Lipoprotein, and Glucose (CHG) Index Is Associated with Renal Survival in Patients with IgA Nephropathy
Provisionally accepted- Department of Nephrology, Hangzhou Hospital of Traditional Chinese Medicine, Hangzhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: The cholesterol, high-density lipoprotein, and glucose (CHG) index has emerged as a novel biomarker for insulin resistance (IR) and metabolic syndrome (MS). However, its prognostic role in IgA nephropathy (IgAN) remains underexplored. This study investigated the association between the CHG index and IgAN and aimed to clarify the importance of the CHG index in evaluating the prognosis of IgAN. Methods: This single-centre retrospective study included 1791 patients with biopsy-confirmed IgAN who had more than 12 months of follow-up from October 2014 to September 2023. The optimal CHG index cut-off for renal endpoints was determined using receiver operating characteristic (ROC) analysis. Associations were assessed via correlation analysis, Cox regression, and Kaplan‒Meier survival analysis. Results: Patients were stratified into three baseline CHG index tertiles. High baseline CHG index was correlated with adverse clinicopathological features and reduced renal survival (Kaplan‒Meier, log-rank=26.51; P<0.001). Correlation analyses revealed that the CHG index was positively associated with tubular atrophy/interstitial fibrosis, as well as intimal thickening and hyaline degeneration of renal arteries (P<0.001). The optimal CHG index cut-off for renal survival was 5.29 (sensitivity=63.1%, specificity=63.0%, AUC=0.646), and patients were divided into a low group (CHG index≤5.29; n=1,096) and a high group (CHG index >5.29; n=695). Subgroup analysis revealed that elevated CHG indices had a more pronounced prognostic value for renal outcomes in This is a provisional file, not the final typeset article subgroups of patients with a BMI≤24.9, a 24-hour urine protein level≤3.5 g, an estimated glomerular filtration rate (eGFR)≤45 mL/min/1.73m², and an Oxford renal pathology classification (MEST-C)T0. Multivariate Cox regression analysis demonstrated that elevated CHG indices were significantly associated with worse renal outcomes in patients with IgAN (adjusted HR: 1.842; 95% CI: 1.044– 3.249; P=0.035). Conclusion: Elevated CHG index is an independent risk factor for predicting renal prognosis in IgAN. Compared with patients with low CHG indices, those with CHG indices > 5.29 have an 84.2% greater risk of poor renal outcomes.
Keywords: The Cholesterol, high-density lipoprotein, and Glucose (CHG) index, IgAnephropathy, Insulin resistance (IR), Renal survival, prognosis
Received: 14 Jun 2025; Accepted: 16 Sep 2025.
Copyright: © 2025 Liu, Tang, Yuan, Gu, Wang, Zhao and Jiang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Xue Jiang, monica_jiang@163.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.